ストックスクリーナーアプリを入手
0.7458
1.50%
0.011
プレマーケット:
.74
-0.0058
-0.78%
Glucotrack Inc (GCTK) 最新ニュース
GlucoTrack Executes Debt-for-Equity Exchange to Reduce Obligations - TipRanks
Glucotrack exchanges $600,000 note for 895,000 shares with investor By Investing.com - Investing.com
Glucotrack Swaps $600,000 Note Portion for 895,000 Shares Under Exchange Agreement - TradingView — Track All Markets
Glucotrack (NASDAQ: GCTK) swaps $600K debt for 895,000 shares - Stock Titan
GlucoTrack stock gains as data backs FDA filing plans for glucose monitoring tech - MSN
Technical Analysis: Is GlucoTrack Inc impacted by rising ratesProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
$Glucotrack (GCTK.US)$ thanks market - Moomoo
RSI Check: Will GlucoTrack Inc benefit from geopolitical trends2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
Glucotrack reports net loss of USD 19.4M in FY 2025 - Medical Buyer
Glucotrack, Inc. 2025 Annual Report – Implantable Continuous Blood Glucose Monitor Development, Regulatory Progress, and Risk Factors 66 - Minichart
Glucotrack FY25 Net Loss Narrows; Plans To Submit An IDE For CBGM In Q2 2026 - RTTNews
GCTK: Improved net loss and cash position support 2026 clinical trial launch for implantable CBGM - TradingView — Track All Markets
Glucotrack (GCTK) advances implantable CBGM but flags going concern risk - Stock Titan
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Glucotrack (NASDAQ: GCTK) trims 2025 loss and readies IDE for implantable CBGM trials - Stock Titan
Glucotrack, Inc. Announces IDE Filing Plans for Continuous Blood Glucose Monitoring Technology and Patents Issued by USPTO - Quiver Quantitative
Glucotrack’s 3-year glucose implant targets a U.S. human trial in 2026 - Stock Titan
GCTK stock is soaring pre-market today — what is fueling the surge? - MSN
Technical Analysis: What analysts say about GlucoTrack Inc stock2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
GlucoTrack Plummets 27%: Is This the Bottom of a Deep Downtrend? A High-Stakes Analysis for 2026 - Bitget
GCTK PE Ratio & Valuation, Is GCTK Overvalued - Intellectia AI
GlucoTrack Prepares FDA Submission for Implantable CBGM Trial - The Globe and Mail
Glucotrack plans FDA submission for implantable glucose monitor By Investing.com - Investing.com Australia
Glucotrack to File for FDA Exemption Based on 2025 Milestones - Yahoo Finance
GCTK Stock Is Soaring Today — What Is Fueling The Surge? - Stocktwits
Glucotrack to Submit IDE Application to FDA in Early Q2 - citybiz
Glucotrack, Inc. (GCTK) Stock: Prepares FDA Submission as Clinical Data Shows Strong Accuracy - parameter.io
Glucotrack plans US trial of implantable glucose monitor this year - MedTech Dive
Microcap MedTech Moving on U.S. Clinical Milestone - The Globe and Mail
GCTK stock GlucoTrack NASDAQ +29.80% on FDA IDE plan 27 Mar 2026: Earnings in focus - Meyka
Latest Developments Propel GCTK Stock with Breakthrough Acquisitions - StocksToTrade
Why Is GlucoTrack Stock Soaring Friday?GlucoTrack (NASDAQ:GCTK) - Benzinga
GlucoTrack (GCTK) Surges 45% in Afternoon Trading—What's Fueling This Unusual Move? - Bitget
Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 Milestones - marketscreener.com
Glucotrack plans FDA submission for implantable glucose monitor - investing.com
Glucotrack to file IDE with FDA in Q2 2026 after successful human trials and new patents - TradingView
GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge? - Stocktwits
Glucotrack (NASDAQ: GCTK) advances implantable CBGM with IDE plan and new patents - Stock Titan
Glucotrack to file significant IDE with FDA for US clinical trial in early Q2 based on critical 2025 milestones - MarketScreener
Glucotrack Plans IDE Submission to FDA in Early Q2 2026 for Non-Invasive Glucose Monitoring Clinical Trials - geneonline.com
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones - marketscreener.com
Is GlucoTrack Inc. a stock for growth or value investorsWeekly Market Outlook & Weekly Top Stock Performers List - baoquankhu1.vn
Sentiment Review: What analysts say about GlucoTrack Inc stockOptions Play & Precise Entry and Exit Recommendations - baoquankhu1.vn
Growth Recap: Is GlucoTrack Inc backed by strong institutional buying2026 Closing Moves & Short-Term High Return Ideas - baoquankhu1.vn
GlucoTrack Shareholders Approve Capital Flexibility and Auditor Ratification - The Globe and Mail
GlucoTrack, Inc. 8-K SEC Filing: Company Details, Nasdaq Listing, and Key Disclosures (March 2026) - Minichart
Glucotrack shareholders approve stock issuances and auditor ratification - Investing.com
Glucotrack (GCTK) investors approve large stock and warrant issuances - Stock Titan
GCTK SEC FilingsGlucotrack 10-K, 10-Q, 8-K Forms - Stock Titan
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit - Yahoo Finance
Chart Watch: Will GlucoTrack Inc benefit from geopolitical trendsMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Why Did Glucotrack Stock Surge 12% Pre-Market Today? - Stocktwits
GCTK Earnings History & Surprises | EPS & Revenue Results | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
GCTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GCTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
0.06%
1.84%
大文字化:
|
ボリューム (24 時間):